Insmed Incorporated: Now Comes The Hard Part

Summary

• Today, we put midcap concern Insmed Incorporated in the spotlight, as the stock has soared since successful Phase 3 trial results in late May.
• The company already has one approved product on the market and is advancing two more candidates within its pipeline.
• Management believes these three compounds could have $8 billion or more in peak sales potential if all indications targeted are eventually approved.
• However, the company is also burning cash and there was a notable uptick in insider selling following the recent spike in the stock.
• The analyst community is quite enamored about the company's prospects, it should be noted.  An analysis around Insmed follows in the paragraphs below.
• Looking for more investing ideas like this one? Get them exclusively at The Biotech Forum. Learn More »

Eoneren

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.